Unique ID issued by UMIN | UMIN000012469 |
---|---|
Receipt number | R000014594 |
Scientific Title | Comparison of Adalimumab and Steroid in Intestinal Behcet's disease |
Date of disclosure of the study information | 2013/12/02 |
Last modified on | 2024/03/31 23:50:37 |
Comparison of Adalimumab and Steroid
in Intestinal Behcet's disease
Castle Study
Comparison of Adalimumab and Steroid
in Intestinal Behcet's disease
Castle Study
Japan |
Intestinal Behcet's disease
Gastroenterology |
Others
NO
Comparison with adalimumab and steroid for the efficacy of remission induction in patients with intestinal Behcet's disease
Safety,Efficacy
Endoscopic efficacy at 12 weeks
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
2
Treatment
Medicine |
Subcutaneous injection of adalumumab with 160mg at 0 week, 80mg at 2 weeks and 40mg every other week after at 4 weeks continuously.
Oral administration of prednisolone with 0.6mg/kg/day during from 1 to 2 weeks, and tapering off until 12 weeks with decreasing dosage 5mg/kg/week approximately
15 | years-old | <= |
Not applicable |
Male and Female
The patients with intestinal Behcet's disease who were refractory to conventional treatment and contained with typical punched-out ulce in the cecum.
1) The patients with simple ulcer disease complicated without general Behcet's symptoms
2) Contraindication of adalimumab administration
a: Severe infectious disease
b: Active tuberculosis
c: Past history for hypersensitivity of adalimumab contents
d: Present or past history for demyelinating disorder
e: Congestive heart failure
3) Contraindication for steroid administration
a: Past history for hypersensitivity of prednisolone contents
4) Pregnant or breast feeding woman
5) Below the age of 15 years old
6) The patients who are unable to provide informed consent
7) The patients who are begun to administrate with more than 10mg/kg steroid within 2 weeks
8) The patients who are administrated with steroid more than 2 weeks
9) The patients who had been administrated with infliximab or adalimumab. However, the patients who were intolerant for infliximab within 2nd infusion (0 week or 2 weeks) can be enrolled.
10) The patients who are added or increased dosage of administration with as follows, 5-aminosalicylates or nutrition therapy within 2 weeks, colchicine or tacrolimus or ciclosporin or methotrexate within 4 weeks, azathioprine or 6-mercaptopurine within 8 weeks
11) Malignancy patient
12) The patients who are contained with untypical lesion for intestinal Behcet's disease
13) The patients who are indicated as insufficient by the physician
50
1st name | Kenji |
Middle name | |
Last name | Watanabe |
Osaka City University
Department of Gastroenterology
545-8585
1-4-3, Asahi-machi, Abeno-ku, Osaka
06-6645-3811
kenjiw1779@gmail.com
1st name | Kenji |
Middle name | |
Last name | Watanabe |
Osaka City University
Department of Gastroenterology
545-8585
1-4-3, Asahi-machi, Abeno-ku, Osaka
06-6645-3811
kenjiw1779@gmail.com
Castle Study Group
none
Self funding
Osaka City University Hospital Certified Review Board
1-2-7-601, Asahi-machi, Abeno-ku, Osaka
06-6645-3435
ethics@med.osaka-cu.ac.jp
NO
2013 | Year | 12 | Month | 02 | Day |
Unpublished
Enrolling by invitation
2013 | Year | 10 | Month | 03 | Day |
2013 | Year | 10 | Month | 03 | Day |
2013 | Year | 12 | Month | 02 | Day |
2025 | Year | 12 | Month | 31 | Day |
2013 | Year | 12 | Month | 02 | Day |
2024 | Year | 03 | Month | 31 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014594
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |